09/29/2025
About ten years ago, Prof. Sylvia Villeneuve and the PREVENT-AD team took a bold step: they decided to add MEG recordings to an already intensive longitudinal study of individuals at risk of Alzheimer’s disease. It was a leap into the unknown, but one that is now paying off. Evidence is mounting that subtle changes in brain activity occur long before symptoms emerge, and may even anticipate the pathological build-up of proteins that drive the disease.
This new paper marks a major milestone for PREVENT-AD. I am deeply grateful to Sylvia and the team for their enthusiasm and resilience over the past decade. Their vision and dedication have led to a series of impactful studies and high-profile publications, and the future promises even more insights as this unique dataset continues to grow.
Read the paper in open access:
The PResymptomatic EValuation of Experimental or Novel Treatments for Alzheimer's Disease (PREVENT-AD) is an investigator-driven study that was created in 2011 and enrolled cognitively normal older ...